Go Pro
NASDAQ:EVLO

Evelo Biosciences (EVLO) Stock Price, News & Analysis

Evelo Biosciences logo

About Evelo Biosciences Stock (NASDAQ:EVLO)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
2,227 shs
Market Capitalization
$2 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evelo Biosciences, Inc. was a clinical-stage biotechnology company focused on developing orally administered medicines that act through the small-intestinal axis. The company’s approach was designed to use specific strains of bacteria or microbial products to influence immune and inflammatory responses throughout the body.

Evelo’s research platform, known as SINTAX, supported the development of product candidates for inflammatory, autoimmune and oncology indications. Its lead programs included EDP1815, an oral microbial therapeutic studied in conditions such as psoriasis and atopic dermatitis, and EDP2939, which was investigated as an immune-modulating treatment for cancer. The company conducted clinical development activities in the United States and other regions.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Evelo Biosciences was formerly listed on the Nasdaq under the symbol EVLO. The company later entered a wind-down process after pursuing strategic alternatives and financial restructuring, and its operations and development programs were substantially discontinued. Because the company is no longer an active biotechnology developer, historical information about its programs represents its activities before that wind-down.

AI Generated. May Contain Errors.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVLO Stock News Headlines

Evelo Biosciences Inc.
Evelo Biosciences
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Evelo Biosciences, Inc. (EVLO)
See More Headlines

EVLO Stock Analysis - Frequently Asked Questions

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its quarterly earnings data on Wednesday, October, 27th. The company reported ($12.60) earnings per share for the quarter, missing the consensus estimate of ($10.80) by $1.80.

Shares of Evelo Biosciences reverse split on Friday, June 30th 2023.The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Evelo Biosciences (EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evelo Biosciences investors own include Sangamo Therapeutics (SGMO), Fulcrum Therapeutics (FULC), Meta Platforms (META) and

Company Calendar

Last Earnings
10/27/2021
Today
9/24/2026
Next Earnings (Estimated)
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:EVLO
CIK
1694665
Fax
N/A
Employees
66
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
18,840,000
Free Float
18,789,000
Market Cap
$2 thousand
Optionable
No Data
Beta
1.50

Social Links

10 Best Stocks to Own - Fall 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:EVLO) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners